Latest & greatest articles for epilepsy

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on epilepsy or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on epilepsy and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for epilepsy

101. National clinical guideline for the assessment and treatment of epilepsy in children and adolescents

National clinical guideline for the assessment and treatment of epilepsy in children and adolescents NATIONAL CLINICAL GUIDELINE FOR THE ASSESSMENT AND TREATMENT OF EPILEPSY IN CHILDREN AND ADOLESCENTS Quick guide National clinical guideline for the assessment and treatment of epilepsy in children and adolescents. Published by the Danish Health Authority, April 2016 Assessment of epilepsy in children and adolescents: v It is good practice not to perform MRI of the brain in children (...) and adolescents aged 2 to 18 years who are diagnosed with classical Rolandic epilepsy, juvenile myoclonic epilepsy, childhood absence epilepsy or juvenile absence epilepsy based on clinical assessment and EEG. v It is good practice to perform long-term video-EEG monitoring in children and adolescents under the age of 18 in case of undiagnosed seizures – both in case of doubt about the classification of epileptic seizures and syndromes and when non-epileptic seizures are suspected. Treatment of epilepsy

Danish National Clinical Guidelines2016

102. Care delivery and self management strategies for children with epilepsy.

Care delivery and self management strategies for children with epilepsy. BACKGROUND: Epilepsy care for children has been criticised for its lack of impact. Various service models and strategies have been developed in response to perceived inadequacies in care provision for children and their families. OBJECTIVES: To compare the effectiveness of any specialised or dedicated intervention for the care of children with epilepsy and their families to the effectiveness of usual care. SEARCH METHODS (...) : We searched the Cochrane Epilepsy Group Specialized Register (9 December 2013), the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library, 2013,Issue 11), MEDLINE (1946 to June week 2, 2013), EMBASE (1988 to week 25, 2013), PsycINFO (1887 to 11 December 2013) and CINAHL Plus (1937 to 11 December 2013). In addition, we contacted experts in the field to seek information on unpublished and ongoing studies, checked the websites of epilepsy organisations and checked

Cochrane2015

103. Interventions for psychotic symptoms concomitant with epilepsy.

Interventions for psychotic symptoms concomitant with epilepsy. BACKGROUND: This is an updated version of the original Cochrane review published in Issue 4, 2008.People suffering from epilepsy have an increased risk of experiencing psychotic symptoms. The psychotic syndromes associated with epilepsy have generally been classified as ictal, postictal, and interictal psychosis. Anticonvulsant drugs have been reported to precipitate psychosis. Moreover, all antipsychotic drugs have the propensity (...) to cause paroxysmal electroencephalogram abnormalities and induce seizures. OBJECTIVES: To evaluate the benefits of interventions used to treat clinically significant psychotic symptoms occurring in people with epilepsy with regard to global improvement, changes in mental state, hospitalization, behavior, quality of life, effect on the frequency of seizures, and interaction with antiepileptic drugs. SEARCH METHODS: We searched the Cochrane Epilepsy Group's Specialized Register (23 March 2015

Cochrane2015

104. Cannabinoids in the Treatment of Epilepsy.

Cannabinoids in the Treatment of Epilepsy. Cannabinoids in the Treatment of Epilepsy. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography Citation manager Format Create File 1 selected item: 26672645 Format MeSH and Other Data E-mail Subject Additional text E-mail (...) Add to Clipboard Add to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2016 Jan 7;374(1):94-5. doi: 10.1056/NEJMc1512758. Epub 2015 Dec 16. Cannabinoids in the Treatment of Epilepsy. , . Comment on [N Engl J Med. 2016] [N Engl J Med. 2015] PMID: 26672645 DOI: [Indexed for MEDLINE] Free full text Publication types MeSH terms Substances Full Text Sources Medical PubMed Commons 0 comments How to cite this comment

NEJM2015

105. Cannabinoids in the Treatment of Epilepsy.

Cannabinoids in the Treatment of Epilepsy. Cannabinoids in the Treatment of Epilepsy. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography Citation manager Format Create File 1 selected item: 26672646 Format MeSH and Other Data E-mail Subject Additional text E-mail (...) Add to Clipboard Add to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2016 Jan 7;374(1):94. Cannabinoids in the Treatment of Epilepsy. . Comment in [N Engl J Med. 2016] Comment on [N Engl J Med. 2015] PMID: 26672646 DOI: [Indexed for MEDLINE] Publication types MeSH terms Substances Full Text Sources Medical PubMed Commons 0 comments How to cite this comment: Supplemental Content Full text links You are here

NEJM2015 Full Text: Link to full Text with Trip Pro

106. Subpial transection surgery for epilepsy.

Subpial transection surgery for epilepsy. BACKGROUND: Nearly 30% of patients with epilepsy continue to have seizures in spite of using several antiepileptic drug (AED) regimens. Such patients are regarded as having refractory, or uncontrolled, epilepsy. No definition of uncontrolled, or medically refractory, epilepsy has been universally accepted, but for the purposes of this review, we will consider seizures as drug resistant if they have failed to respond to a minimum of two AEDs (...) . It is believed that early surgical intervention may prevent seizures at a younger age, which, in turn, may improve the intellectual and social status of children. Many types of surgery are available for treatment of refractory epilepsy; one such procedure is known as subpial transection. OBJECTIVES: To determine the benefits and adverse effects of subpial transection for partial-onset seizures and generalised tonic-clonic seizures in children and adults. SEARCH METHODS: We searched the Cochrane Epilepsy

Cochrane2015

107. The Importance of Checking Impedance: Misinterpretation of Deep Brain Stimulation Dysfunction as Epilepsy

The Importance of Checking Impedance: Misinterpretation of Deep Brain Stimulation Dysfunction as Epilepsy 30363556 2018 11 14 2330-1619 3 2 2016 Mar-Apr Movement disorders clinical practice Mov Disord Clin Pract The Importance of Checking Impedance: Misinterpretation of Deep Brain Stimulation Dysfunction as Epilepsy. 206-208 10.1002/mdc3.12267 Wolf Marc E ME Department of Neurology Universitätsmedizin Mannheim University of Heidelberg Mannheim Germany. Blahak Christian C Department of Neurology (...) Universitätsmedizin Mannheim University of Heidelberg Mannheim Germany. Krauss Joachim K JK Department of Neurosurgery Hannover Medical School Hannover Germany. eng Journal Article 2015 11 27 United States Mov Disord Clin Pract 101630279 2330-1619 deep brain stimulation dystonia epilepsy globus pallidus internus side effects 2015 05 28 2015 09 01 2015 09 04 2018 10 27 6 0 2015 11 27 0 0 2015 11 27 0 1 epublish 30363556 10.1002/mdc3.12267 MDC312267 PMC6178714 N Engl J Med. 2006 Nov 9;355(19):1978-90 17093249

Movement disorders clinical practice2015 Full Text: Link to full Text with Trip Pro

108. Hospital-Diagnosed Pertussis Infection in Children and Long-term Risk of Epilepsy.

Hospital-Diagnosed Pertussis Infection in Children and Long-term Risk of Epilepsy. IMPORTANCE: Pertussis is associated with encephalopathy and seizures in infants. However, the risk of childhood epilepsy following pertussis is unknown. OBJECTIVE: To examine whether pertussis is associated with the long-term risk of epilepsy. DESIGN, SETTING, AND PARTICIPANTS: We used individually linked data from population-based medical registries covering all Danish hospitals to identify a cohort of all (...) patients with pertussis born between 1978 and 2011, followed up through 2011. We used the Civil Registration System to identify 10 individuals from the general population for each patient with pertussis, matched on sex and year of birth. EXPOSURES: Inpatient or hospital-based outpatient diagnosis of pertussis. MAIN OUTCOMES AND MEASURES: Cumulative incidence and hazard ratio of time to hospital-based epilepsy diagnosis (pertussis cohort vs general population cohort), adjusted for birth year, sex

JAMA2015 Full Text: Link to full Text with Trip Pro

109. Sulthiame add-on therapy for epilepsy.

Sulthiame add-on therapy for epilepsy. BACKGROUND: Epilepsy is a common neurological condition characterised by recurrent seizures. Most patients respond to conventional antiepileptic drugs, however, around 30% will continue to experience seizures despite multiple antiepileptic drugs. Sulthiame, also known as sultiame, is a widely used antiepileptic drug in Europe and Israel. We present a summary of the evidence for the use of sulthiame as add-on therapy in epilepsy. OBJECTIVES: To compare (...) the efficacy and side-effect profile of sulthiame as add-on therapy compared with placebo or another antiepileptic drug. SEARCH METHODS: We searched the Cochrane Epilepsy Group's Specialised Register, the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, ClinicalTrials.gov and the WHO ICTRP Search Portal on 11 August 2015. No language restrictions were imposed. We contacted the manufacturers of sulthiame and researchers in the field to seek any ongoing or unpublished studies. SELECTION

Cochrane2015

110. Stiripentol for focal refractory epilepsy.

Stiripentol for focal refractory epilepsy. BACKGROUND: This is an updated version of the original Cochrane review published in 2014 (Issue 1). For nearly 30% of people with epilepsy, seizures are not controlled by current treatments. Stiripentol is a new antiepileptic drug (AED) that was developed in France and was approved by the European Medicines Agency (EMA) in 2007 for the treatment of Dravet syndrome as adjunctive therapy with valproate and clobazam, with promising effects. OBJECTIVES (...) : To evaluate the efficacy and tolerability of stiripentol as add-on treatment for patients with focal refractory epilepsy who are taking AEDs. SEARCH METHODS: We searched the Cochrane Epilepsy Group Specialised Register (10 August 2015), the Cochrane Central Register of Controlled Trials (CENTRAL; August 2015, Issue 8)and MEDLINE (Ovid) (1946 to 10 August 2015). We contacted Biocodex (the manufacturer of stiripentol) and epilepsy experts to identify published, unpublished and ongoing trials. SELECTION

Cochrane2015

111. Cannabinoids in the Treatment of Epilepsy.

Cannabinoids in the Treatment of Epilepsy. Cannabinoids in the Treatment of Epilepsy. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography Citation manager Format Create File 1 selected item: 26352816 Format MeSH and Other Data E-mail Subject Additional text E-mail (...) Add to Clipboard Add to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2015 Sep 10;373(11):1048-58. doi: 10.1056/NEJMra1407304. Cannabinoids in the Treatment of Epilepsy. , . Comment in [N Engl J Med. 2016] N Engl J Med. 2016 Jan 7;374(1):94. PMID: 26352816 DOI: [Indexed for MEDLINE] Publication type MeSH terms Substances Full Text Sources Other Literature Sources Medical Miscellaneous PubMed Commons 0 comments How

NEJM2015

112. Non-pharmacological interventions for people with epilepsy and intellectual disabilities.

Non-pharmacological interventions for people with epilepsy and intellectual disabilities. BACKGROUND: Approximately 30% of patients with epilepsy remain refractory to drug treatment and continue to experience seizures whilst taking one or more antiepileptic drugs (AEDs). Several non-pharmacological interventions that may be used in conjunction with or as an alternative to AEDs are available for refractory patients. In view of the fact that seizures in people with intellectual disabilities (...) are often complex and refractory to pharmacological interventions, it is evident that good quality randomised controlled trials (RCTs) are needed to assess the efficacy of alternatives or adjuncts to pharmacological interventions.This is an updated version of the original Cochrane review (Beavis 2007) published in The Cochrane Library (2007, Issue 4). OBJECTIVES: To assess data derived from randomised controlled trials of non-pharmacological interventions for people with epilepsy and intellectual

Cochrane2015

113. Perampanel for tonic-clonic seizures in idiopathic generalized epilepsy: A randomized trial

Perampanel for tonic-clonic seizures in idiopathic generalized epilepsy: A randomized trial 26296511 2015 11 30 2015 12 16 2016 12 15 1526-632X 85 11 2015 Sep 15 Neurology Neurology Perampanel for tonic-clonic seizures in idiopathic generalized epilepsy A randomized trial. 950-7 To assess efficacy and safety of adjunctive perampanel in patients with drug-resistant, primary generalized tonic-clonic (PGTC) seizures in idiopathic generalized epilepsy (IGE). In this multicenter, double-blind study (...) with drug-resistant PGTC seizures in IGE. French Jacqueline A JA Krauss Gregory L GL Wechsler Robert T RT Wang Xue-Feng XF DiVentura Bree B Brandt Christian C Trinka Eugen E O'Brien Terence J TJ Laurenza Antonio A Patten Anna A Bibbiani Francesco F eng ClinicalTrials.gov NCT01393743 Journal Article Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't United States Neurology 0401060 0028-3878 0 Anticonvulsants 0 Pyridones H821664NPK perampanel Epilepsy, Idiopathic Generalized

EvidenceUpdates2015 Full Text: Link to full Text with Trip Pro

114. Neuropsychological and psychological interventions for people with newly diagnosed epilepsy.

Neuropsychological and psychological interventions for people with newly diagnosed epilepsy. BACKGROUND: Many people with epilepsy report experiencing psychological difficulties such as anxiety, depression and neuropsychological deficits including memory problems. Research has shown that these difficulties are often present not only for people with chronic epilepsy but also for people with newly diagnosed epilepsy. Despite this, there are very few published interventions that detail means (...) to help people with newly diagnosed epilepsy manage these problems. OBJECTIVES: To identify and assess possible psychological and neuropsychological interventions for adults with newly diagnosed epilepsy. SEARCH METHODS: We searched the following databases on 30 June 2015: the Cochrane Epilepsy Group Specialized Register, the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE (Ovid), SCOPUS, PsycINFO, CINAHL, ClinicalTrials.gov and the World Health Organization (WHO) International

Cochrane2015

115. Corticosteroids including ACTH for childhood epilepsy other than epileptic spasms.

Corticosteroids including ACTH for childhood epilepsy other than epileptic spasms. BACKGROUND: This is an updated version of the original Cochrane review published in Issue 1, 2007.Epilepsy is a disorder with recurrent epileptic seizures. Corticosteroids have been used in the treatment of children with epilepsy and have significant adverse effects. Their efficacy and tolerability have not been clearly established. OBJECTIVES: To determine the efficacy, in terms of seizure control, improvements (...) in cognition and in quality of life and tolerability of steroids compared to placebo or other antiepileptic drugs in children with epilepsy, excluding epileptic spasms. SEARCH METHODS: We searched the following databases: The Cochrane Epilepsy Group Specialized Register (1 August 2014); CENTRAL, (The Cochrane Library Issue 7, July 2014); MEDLINE (1946 to 1 August 2014); EMBASE (1966 to December 2004); Database of Abstracts of Reviews of Effectiveness (DARE; Issue 3 of the database published in The Cochrane

Cochrane2015

116. Epilepsy after aneurysmal subarachnoid hemorrhage: A population-based, long-term follow-up study

Epilepsy after aneurysmal subarachnoid hemorrhage: A population-based, long-term follow-up study 25948726 2015 06 02 2015 08 19 2016 03 09 1526-632X 84 22 2015 Jun 02 Neurology Neurology Epilepsy after aneurysmal subarachnoid hemorrhage: A population-based, long-term follow-up study. 2229-37 10.1212/WNL.0000000000001643 The aim was to elucidate the incidence and risk factors of epilepsy after subarachnoid hemorrhage (SAH) from saccular intracranial aneurysm (sIA) in a population-based cohort (...) . The Kuopio sIA Database (www.uef.fi/ns) includes all unruptured and ruptured sIA cases admitted to the Kuopio University Hospital from its defined catchment population in Eastern Finland. The use of prescribed medicines, including reimbursable antiepileptic drugs, has been entered from the Finnish national registries. The cumulative incidence and independent risk factors of epilepsy and death were analyzed in 876 patients with sIA-SAH admitted from 1995 to 2007. The competing risks analysis was used

EvidenceUpdates2015

117. Yoga for epilepsy.

Yoga for epilepsy. BACKGROUND: This is an updated version of the original Cochrane review published in The Cochrane Library, Issue 1, 2002.Yoga may induce relaxation and stress reduction, and influence the electroencephalogram and the autonomic nervous system, thereby controlling seizures. Yoga would be an attractive therapeutic option for epilepsy if proved effective. OBJECTIVES: To assess whether people with epilepsy treated with yoga:(a) have a greater probability of becoming seizure free;(b (...) ) have a significant reduction in the frequency or duration of seizures, or both; and(c) have a better quality of life. SEARCH METHODS: We searched the Cochrane Epilepsy Group Specialized Register (26 March 2015), the Cochrane Central Register of Controlled Trials (CENTRAL, The Cochrane Library, 26 March 2015), MEDLINE (Ovid, 1946 to 26 March 2015), SCOPUS (1823 to 9 January 2014), ClinicalTrials.gov (26 March 2015), the World Health Organization (WHO) International Clinical Trials Registry Platform

Cochrane2015

118. Perampanel efficacy and tolerability with enzyme-inducing AEDs in patients with epilepsy

Perampanel efficacy and tolerability with enzyme-inducing AEDs in patients with epilepsy 25878177 2015 05 12 2015 07 23 2017 02 20 1526-632X 84 19 2015 May 12 Neurology Neurology Perampanel efficacy and tolerability with enzyme-inducing AEDs in patients with epilepsy. 1972-80 10.1212/WNL.0000000000001558 Evaluate the impact of concomitant enzyme (CYP3A4)-inducer antiepileptic drugs (EIAEDs) on the efficacy and safety of perampanel in patients from the 3 phase-III clinical trials. Patients (...) of Excessive Somnolence chemically induced diagnosis Dizziness chemically induced diagnosis Dose-Response Relationship, Drug Double-Blind Method Drug Administration Schedule Drug Combinations Drug Interactions Epilepsy complications diagnosis drug therapy Fatigue chemically induced diagnosis Female Humans Internationality Male Mental Disorders chemically induced diagnosis Pyridones administration & dosage adverse effects Treatment Outcome PMC4433458 2014 01 16 2015 01 28 2015 4 17 6 0 2015 4 17 6 0 2015 7

EvidenceUpdates2015 Full Text: Link to full Text with Trip Pro

119. Epilepsy drug Kaneuron: hazardous packaging

Epilepsy drug Kaneuron: hazardous packaging Prescrire IN ENGLISH - Spotlight ''Epilepsy drug Kaneuron°: hazardous packaging '', 1 April 2015 {1} {1} {1} | | > > > Epilepsy drug Kaneuron°: hazardous packaging Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |   |  Spotlight Epilepsy drug Kaneuron°: hazardous packaging Because of medication errors, the dosing syringe (...) of the drinkable phenobarbital solution has been replaced. But the packaging is still hazardous: two dosing devices are presented side by side and the bottle has no child-proof cap. In France, a drinkable phenobarbital solution is authorised as a treatment for adults and children for partial and generalised epilepsy. The use of phenobarbital is limited because of sedation and behavioural disorders, especially in children, but sometimes it is a useful option. The packaging of Kaneuron° contains two dosing

Prescrire2015

120. Development and validation of nomograms to provide individualised predictions of seizure outcomes after epilepsy surgery: a retrospective analysis

Development and validation of nomograms to provide individualised predictions of seizure outcomes after epilepsy surgery: a retrospective analysis 25638640 2015 03 02 2015 04 28 2015 08 11 1474-4465 14 3 2015 Mar The Lancet. Neurology Lancet Neurol Development and validation of nomograms to provide individualised predictions of seizure outcomes after epilepsy surgery: a retrospective analysis. 283-90 10.1016/S1474-4422(14)70325-4 S1474-4422(14)70325-4 Half of patients who have resective brain (...) surgery for drug-resistant epilepsy have recurrent postoperative seizures. Although several single predictors of seizure outcome have been identified, no validated method incorporates a patient's complex clinical characteristics into an instrument to predict an individual's post-surgery seizure outcome. We developed nomograms to predict complete freedom from seizures and Engel score of 1 (eventual freedom from seizures allowing for some initial postoperative seizures, or seizures occurring only

EvidenceUpdates2015